Skip to main
FDMT

FDMT Stock Forecast & Price Target

FDMT Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

4D Molecular Therapeutics is a biotechnology company focused on developing gene therapy treatments for a variety of diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Their portfolio of gene therapy product candidates has shown promising results in clinical trials, reducing technology risk and validating the potential for widespread use. However, there are risks associated with clinical trial outcomes and manufacturing challenges, which may impact the company's ability to bring these treatments to market and achieve peak sales forecasts.

Bears say

4D Molecular Therapeutics is a biotechnology company that has built a portfolio of promising gene therapy products for ophthalmology, cardiology, and pulmonology. However, the company faces potential competition from other emerging therapies and could face challenges in manufacturing its products, which could impact its financials and lower its potential for profitability. Additionally, there are risks associated with the success of its clinical trials and the need for additional financing, which could result in share dilution for shareholders. These factors contribute to the negative outlook for 4D Molecular Therapeutics's stock.

FDMT has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 4D Molecular Therapeutics (FDMT) Forecast

Analysts have given FDMT a Strong Buy based on their latest research and market trends.

According to 6 analysts, FDMT has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

4D Molecular Therapeutics (FDMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.